NCT07275918
Recruiting
Phase 1
A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SA1211 Injection in Healthy Participants and Participants With Chronic Hepatitis B
Suzhou Siran Biotechnology Co.,Ltd.1 site in 1 country80 target enrollmentStarted: November 25, 2025Last updated:
Overview
- Phase
- Phase 1
- Status
- Recruiting
- Sponsor
- Suzhou Siran Biotechnology Co.,Ltd.
- Enrollment
- 80
- Locations
- 1
- Primary Endpoint
- Number of participants with AEs, SAEs and abnormal laboratory testings
Overview
Brief Summary
The goal of this clinical trial is to evaluate the safety, tolerability, immunogenicity and Pharmacokinetics (PK) characteristics of SA1211 Injection in healthy volunteers (Part A) and participants with chronic hepatitis B (CHB, Part B), and assess its preliminary efficacy in participants with chronic hepatitis B (CHB). The main questions it aims to answer are:
What are the safety, tolerability, immunogenicity and PK characteristics of a single subcutaneous injection of SA1211 Injection in healthy volunteers (Part A)? What are the safety, tolerability, immunogenicity and PK characteristics of multiple subcutaneous injections of SA1211 Injection in participants with CHB (Part B)? What is the preliminary efficacy of SA1211 Injection in participants with CHB (Part B)?
Participants will:
- Part A (healthy volunteers): Receive a single subcutaneous injection of SA1211 Injection or placebo and complete relevant safety, tolerability and PK monitoring as required.
- Part B (participants with CHB): Receive multiple subcutaneous injections of SA1211 Injection or placebo and complete relevant safety, tolerability, PK monitoring and preliminary efficacy assessment as required.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Sequential
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to 65 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Able to correctly understand and sign the informed consent form in writing.
- •Male or female participants.
- •For healthy participants: aged 18-55 years old (inclusive of the cut-off values).
- •For participants with chronic hepatitis B (CHB): aged 18-65 years old (inclusive of the cut-off values).
- •Body Mass Index (BMI) meets the following requirements.
- •For healthy participants: within the range of 18-28 kg/m² (inclusive of the cut-off values).
- •For participants with chronic hepatitis B (CHB): within the range of 18-32 kg/m² (inclusive of the cut-off values).
- •During the screening period, the results of the following examinations are either normal or abnormal but not clinically insignificant:
- •\- Clinical laboratory tests: complete blood count, blood biochemistry, coagulation function, urine routine. Thyroid function test. 12-lead electrocardiogram (ECG). Abdominal ultrasound. Posteroanterior chest X-ray.
- •For participants with chronic hepatitis B (CHB): documented hepatitis B virus (HBV) infection for at least 6 months before screening, with positive hepatitis B surface antigen (HBsAg) and/or positive HBV deoxyribonucleic acid (HBV DNA).
Exclusion Criteria
- •Participants with concurrent hepatitis C virus (HCV), human immunodeficiency virus (HIV) or syphilis infection; or those previously diagnosed with hepatitis A, D, or E who have not been cured.
- •Participants with severe diseases, including but not limited to diseases of the nervous, cardiovascular, hematological and lymphatic, immune, renal, hepatic, thyroid, gastrointestinal, respiratory, metabolic, and skeletal systems, as well as a history of malignant tumors.
- •Participants with severe mental illness or uncontrolled mental disorders, including but not limited to schizophrenia, bipolar disorder, or depression.
- •Participants with a systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg at screening, who are deemed unsuitable for the study by the investigator.
- •Participants who have undergone major surgery within 6 months before screening, or plan to undergo surgery during the study period.
- •Participants with severe infection or trauma within 4 weeks before screening.
- •Participants with a severe allergic constitution, or a confirmed allergy to this product or its formulation components.
- •Participants who smoked more than 5 cigarettes per day or the equivalent amount of tobacco within 3 months before screening.
- •Participants deemed unsuitable for the trial by the investigator due to other factors.
Arms & Interventions
Chronic Hepatitis B
Experimental
Intervention: SA1211 injection placebo (Drug)
Healthy Participants
Experimental
Intervention: SA1211 injection (Drug)
Healthy Participants
Experimental
Intervention: SA1211 injection placebo (Drug)
Chronic Hepatitis B
Experimental
Intervention: SA1211 injection (Drug)
Outcomes
Primary Outcomes
Number of participants with AEs, SAEs and abnormal laboratory testings
Time Frame: Approximate 24 weeks
AEs: Adverse Events. SAEs: Serious Adverse Events.
Secondary Outcomes
- Cmax: maximum concentration(Pre-dose, multiple time-points post dose until 48 hours)
- Tmax(Pre-dose, multiple time-points post dose until 48 hours)
- AUC0-t(Pre-dose, multiple time-points post dose until 48 hours)
- AUC0-inf(Pre-dose, multiple time-points post dose until 48 hours)
- t1/2(Pre-dose, multiple time-points post dose until 48 hours)
- λz(Pre-dose, multiple time-points post dose until 48 hours)
- Vd/F(Pre-dose, multiple time-points post dose until 48 hours)
- CL/F(Pre-dose, multiple time-points post dose until 48 hours)
- Css (Steady-State Concentration)(Pre-dose, multiple time-points post dose until 48 hours)
- DF (Degree of Fluctuation)(Pre-dose, multiple time-points post dose until 48 hours)
- The number of participants with chronic hepatitis B (CHB) who achieved hepatitis B surface antigen (HBsAg) clearance(Approximate 24 weeks)
- Maximum HBsAg Decline in CHB Participants Within 24 Weeks (log10)(Approximate 24 weeks)
- The number of CHB Participants with HBsAg Seroconversion at each assessment time Point within 24 weeks(Approximate 24 weeks)
- The number of CHB participants who achieved HBeAg seronegativity at each assessment time point within 24 weeks(Approximate 24 weeks)
- The number of participants with immunogenicity (i.e., anti-drug antibodies [ADAs])(Approximate 24 weeks)
- The change in QTcF relative to baseline and the change relative to placebo(Approximate 24 weeks)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
A Study of HS-10518 in Healthy Adult Premenopausal Females in ChinaNCT07264192West China Second University Hospital60
Recruiting
Phase 1
Evaluation of the Safety, Tolerability and Pharmacokinetics of HY6725 in Healthy Adult ParticipantsNCT07262281Newsoara Biopharma Co., Ltd.74
Recruiting
Phase 2
Study Evaluating ISM5411 Administered Orally to Subjects With Active Ulcerative Colitis (BETHESDA)NCT07265570InSilico Medicine Hong Kong Limited80
Not yet recruiting
Not Applicable
A 2-Part Study to Assess Efficacy, Safety and Tolerability of BMB-101 for the Treatment of Patients With Prader-Willi Syndrome.NCT07266324Bright Minds Biosciences Pty Ltd16
Recruiting
Phase 2
A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLCNCT07264816Sichuan Baili Pharmaceutical Co., Ltd.80